Panther’s MAP delivers small amounts of shelf-stable treatments to precise locations in the skin with the highest concentration of immune cells. Powered by technology, the MAP enables patients to self-apply treatments and share results with physicians and providers anywhere, anytime. (Credit: Panther Life Sciences)

Panther Life Sciences  , which develops shelf-stable treatments to deliver better health for all, has formed a strategic alliance with Pitt BioForge  , a cutting-edge biotechnology manufacturing initiative based in Pittsburgh, PA. The partnership seeks to advance the production of Panther’s Microarray Patch (MAP) platform, accelerating and scaling manufacturing innovations to deliver thermostable, direct-to-consumer, data-centric treatments for a wide range of ailments.

Panther Life Sciences is commercializing licensed technology developed at the University of Pittsburgh and Carnegie Mellon University. This technology established foundational scientific know-how for skin biology and MAP technology, enabling Panther to develop a pipeline of skin-based treatments for therapeutic applications. MAPs consists of an array of microscopic projections that can penetrate the upper layers of the skin and deliver a wide variety of compounds. The collaboration with BioForge underscores Panther’s commitment to leveraging Pittsburgh’s robust ecosystem of academic excellence and industrial innovation to produce scalable MAP-based solutions for broad access to life-changing treatments.

“Our collaboration with BioForge marks a pivotal step in advancing the large-scale manufacturing of microarray patches,” says Carlos Bhola, CEO of Panther Life Sciences. “By automating key processes, we aim to significantly reduce production costs while upholding the highest quality standards. Our Microarray patches promise fewer side effects, greater efficacy and accessibility, and an outstanding user experience. They can be sent directly to patients for self-administration anywhere, anytime, and offer a range of data-centric features such as feedback to providers and treatment developers.”

Panther’s project at BioForge is focused on accelerating scaled manufacturing of MAPs. Central to the Panther-BioForge project is the development and demonstration of an improved, automated manufacturing line designed to:

  • Reduce labor costs through cutting-edge automation.
  • Enhance production scalability.
  • Deliver cost-effective solutions to meet global healthcare demands.

“At BioForge, we are committed to transforming theory into practice by prototyping innovative manufacturing processes,” says Dr. Kaigham Gabriel, CEO of BioForge. “This project with Panther Life Sciences, one of the first three under way at BioForge, represents the type of manufacturing challenge BioForge was created to solve.”

Panther Life Sciences’ collaboration with BioForge is set to achieve its key manufacturing innovation milestones within a year. Through this rapid development timeline, the two partners seek to translate the developed process for cGMP manufacturing of MAPs.

Topics:
Drug Delivery Drug Delivery Manufacturing & Prototyping Market Reports Medical

More From SAE Media Group